Filtered By:
Condition: Arthritis
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 33 results found since Jan 2013.

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Prevention of Stroke in Rheumatoid Arthritis
Opinion statement Recognizing that systemic inflammation is a major contributor to the increased risk of cardiovascular disease (CVD), including stroke, in rheumatoid arthritis (RA) serves as the basis for prevention strategies for cerebrovascular disease in RA. In addition to traditional cardiovascular risk factors, recognize that RA may be an independent risk factor for cerebrovascular accident (CVA). The risk of CVD should be assessed in each patient with RA, utilizing modified risk score calculators. Careful monitoring and control of systemic inflammation should be undertaken in conjunction with assessing eac...
Source: Current Treatment Options in Neurology - May 18, 2015 Category: Neurology Source Type: research

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Risk-benefit profile of statin therapy 'may be more positive than expected'
This study showed that providing an effective low-cost statin therapy to 10,000 patients for five years would prevent major cardiovascular events such as heart attacks, strokes and coronary artery bypasses in 1,000 people with preexisting vascular disease, as well as 500 people who are at increased risk but have not yet had a vascular event. By contrast, only 50 to 100 cases of symptomatic adverse events would be expected over the same period, as well as 50 to 100 new cases of diabetes, five cases of myopathy and between five and ten haemorrhagic strokes. Should statins be more widely used? Currently, about six million peo...
Source: Arthritis Research UK - September 8, 2016 Category: Rheumatology Source Type: news

Anti-inflammatory drug may help prevent heart attacks
Conclusion This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past. But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose. Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection. They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes?
ConclusionFindings from the present study suggest that while CVD risk in RA is elevated, it is lower in magnitude compared to the CVD risk associated with diabetes. It therefore may not be appropriate to consider RA a diabetes risk‐equivalent with respect to hyperlipidemia management.This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - February 6, 2018 Category: Rheumatology Authors: Jeffrey R Curtis, Shuo Yang, Jasvinder A. Singh, Fenglong Xie, Lang Chen, Huifeng Yun, Paul Muntner, Shia T Kent, Emily B. Levitan, Monika M. Safford, Kenneth G. Saag, Jie Zhang Tags: Brief Report Source Type: research

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Statins safe for rheumatoid arthritis patients
Patients with rheumatoid arthritis are likely to experience the same level of cardiovascular benefits as other individuals Related items fromOnMedica Lifestyle intervention in type 2 diabetes can have long-term effect Heart disease and stroke deaths plummet in Scotland Brexit could result in thousands of extra CVD deaths CHD and stroke risk seriously elevated with just one daily cigarette Obesity associated with worse mortality and higher CVD risk
Source: OnMedica Latest News - April 15, 2019 Category: UK Health Source Type: news

Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news

Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.
CONCLUSION: Methotrexate at low doses, such those used for maintenance therapy of RA, predicted a decreased risk of CVE. Since methotrexate doesn't interfere with blood lipids, platelet aggregation or insulin resistance, the protective association may originate from mechanisms other than those exerted by antiplatelet drugs or statins. PMID: 25697810 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - February 16, 2015 Category: Cardiology Authors: De Vecchis R, Baldi C, Palmisani L Tags: Anadolu Kardiyol Derg Source Type: research

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research